Chemotherapy with or without bevacizumab should be the standard of care for first-line unresectable epithelioid mesothelioma
dc.contributor.author | Fennell, Dean | |
dc.contributor.author | Dulloo, Sean | |
dc.date.accessioned | 2022-03-09T15:13:00Z | |
dc.date.available | 2022-03-09T15:13:00Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Fennell, D. A., & Dulloo, S. (2022). Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(1), 34–37. https://doi.org/10.1016/j.jtho.2021.08.004 | en_US |
dc.identifier.other | 10.1016/j.jtho.2021.08.004 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/15224 | |
dc.description.abstract | No abstract available. | |
dc.description.uri | https://www.jto.org/article/S1556-0864(21)02395-9/fulltext | en_US |
dc.language.iso | en | en_US |
dc.subject | antineoplastic combined chemotherapy protocols | en_US |
dc.subject | bevacizumab | en_US |
dc.subject | mesothelioma | en_US |
dc.subject | lung neoplasms | en_US |
dc.title | Chemotherapy with or without bevacizumab should be the standard of care for first-line unresectable epithelioid mesothelioma | en_US |
dc.type | Article | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |
rioxxterms.version | NA | en_US |
rioxxterms.versionofrecord | https://doi.org/10.1016/j.jtho.2021.08.004 | en_US |
rioxxterms.type | Journal Article/Review | en_US |
refterms.panel | Unspecified | en_US |
refterms.dateFirstOnline | 2022 | |
html.description.abstract | No abstract available. | en_US |
rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |